To the full analysis
Becton, Dickinson stock: growth
BDXBecton, Dickinson reported $19.46B in revenue for fiscal 2026, down 10.9% on the prior year, up 0.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.1%
per year from 2007 to 2026, per share 5.4%
Earnings (Annual rate)
1.3%
per year from 2007 to 2026, per share 0.7%
Free cash flow (Annual rate)
8.2%
per year from 2007 to 2026, per share 7.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 0.3% | 4.5% | 6.1% |
| Revenue per share | 1.1% | 1.8% | 5.4% |
| Earnings | −11.3% | 1.6% | 1.3% |
| Earnings per share | −9.9% | −1.1% | 0.7% |
| Free cash flow | −3.0% | 4.8% | 8.2% |
| Free cash flow per share | −2.3% | 2.0% | 7.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $6.36B | $890.03M | $661.71M |
| 2008 | $7.07B | $1.13B | $1.04B |
| 2009 | $6.99B | $1.23B | $1.02B |
| 2010 | $7.12B | $1.32B | $1.11B |
| 2011 | $7.58B | $1.27B | $1.11B |
| 2012 | $7.71B | $1.17B | $1.21B |
| 2013 | $8.05B | $1.29B | $919M |
| 2014 | $8.45B | $1.19B | $1.09B |
| 2015 | $10.28B | $695M | $1.1B |
| 2016 | $12.48B | $976M | $1.84B |
| 2017 | $12.09B | $1.1B | $1.82B |
| 2018 | $15.98B | $311M | $1.97B |
| 2019 | $17.29B | $1.23B | $2.37B |
| 2020 | $16.07B | $874M | $2.73B |
| 2021 | $19.13B | $2.09B | $3.42B |
| 2022 | $18.87B | $1.78B | $1.66B |
| 2023 | $19.37B | $1.48B | $2.12B |
| 2024 | $20.18B | $1.71B | $3.07B |
| 2025 | $21.84B | $1.68B | $2.67B |
| 2026 | $19.46B | $1.15B | $2.93B |
Revenue by segment
How Becton, Dickinson and Company makes its money and how that has shifted. Names are as the company reports them.
- Medical52%
- Interventional24%
- Life Sciences24%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Medical | $8.84B | $9.5B | $10.07B | $11.46B | 52.5% |
| Interventional | $4.46B | $4.74B | $4.98B | $5.22B | 23.9% |
| Life Sciences | $5.56B | $5.13B | $5.19B | $5.17B | 23.7% |
| Total revenue | $18.87B | $19.37B | $20.18B | $21.84B | 100% |
Revenue by region
Where Becton, Dickinson and Company generates its revenue.
- United States59%
- Europe22%
- Asia14%
- Other6%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| United States | $10.72B | $11.11B | $11.66B | $12.79B | 58.6% |
| Europe | $4.04B | $4.24B | $4.4B | $4.73B | 21.7% |
| Asia | $3.05B | $2.91B | $2.91B | $3.09B | 14.2% |
| Other | $1.06B | $1.1B | $1.21B | $1.23B | 5.6% |
| Total revenue | $18.87B | $19.37B | $20.18B | $21.84B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Sep 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Jul 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.